此时的贝娅塔已经没有好的治疗选择，作为克罗地亚萨格勒布大学（University of Zagreb）的病毒学家，她在研究文献后决定亲自动手，使用一种尚未在乳腺癌中经过证实的疗法——溶瘤病毒疗法（Oncolytic ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Patients with dMMR colon cancer in a trial for two neoadjuvant cycles of nivolumab/ipilimumab or nivolumab/relatlimab, had ...

前言在非小细胞肺癌（NSCLC）的治疗中，免疫治疗的出现可谓具有划时代意义。而随着近年来相关研究的蓬勃开展，围术期免疫治疗逐渐成为提高患者生存率的关键手段之一，但这一治疗模式也对外科医师带来了新的挑战。近期，中国医学科学院肿瘤医院高树庚教授团队发表了 ...

Neoadjuvant atezolizumab has a low rate of significant toxicity or disease progression in patients with advanced cSCC. The high pathological response rate can confer a clinical benefit from reduced ...

Grade 3 or higher adverse events were seen in one (5%) patient who developed pneumonitis after the first dose of atezolizumab. Neoadjuvant atezolizumab is feasible and well tolerated in patients with ...

Atossa Therapeutics has strong financials with $79.5 million in cash and a cash runway of 13-14 quarters, minimizing ...

Treatment with nivolumab reduced the risk of disease recurrence, progression or death by 42% compared with placebo. The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) with ...

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

The analysis showed an approximate 40% reduction in the risk of disease recurrence or death after surgery among patients who received at least one dose of adjuvant nivolumab following neoadjuvant ...

BOT/BAL represents a paradigm shift, in how we approach cancer treatment. In the neoadjuvant setting, for example, BOT/BAL has demonstrated the potential to address diseases such as MSS colorectal ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...